La evidencia y el debate clínico del nuevo SLI-LNG 19,5 mg y su uso en la mujer nulípara a revisión

Inmaculada Parra , Jose C. Quílez , Mercedes Andeyro , Paloma Lobo , Ignacio Cristóbal , Francisca Martínez
{"title":"La evidencia y el debate clínico del nuevo SLI-LNG 19,5 mg y su uso en la mujer nulípara a revisión","authors":"Inmaculada Parra ,&nbsp;Jose C. Quílez ,&nbsp;Mercedes Andeyro ,&nbsp;Paloma Lobo ,&nbsp;Ignacio Cristóbal ,&nbsp;Francisca Martínez","doi":"10.1016/j.medre.2018.04.001","DOIUrl":null,"url":null,"abstract":"<div><p>The high rate of unwanted pregnancies results in a high social and economic impact worldwide. One of the most important strategies to reduce this problem is to increase the use of long-acting reversible contraceptive (LARC) methods, due to their efficacy, cost-effectiveness and the independence that these methods provide to their users. LARC methods have been shown to be safe for most women, regardless of age and parity. Kyleena<sup>®</sup> is the new LARC option. A new levonorgestrel intrauterine system (LNG-IUS) containing 19.5<!--> <!-->mg of levonorgestrel and provides a high contraceptive efficacy over 5<!--> <!-->years of use, with a cumulative 5-year Pearl Index of 0.29. Its small size allows a narrower insertion tube to be used and is more suitable for nulliparous women or those women with a narrower cervical canal. In addition to the contraceptive efficacy, Kyleena<sup>®</sup> may benefit users by providing a reduction in the duration and volume of menstrual bleeding. Many women and healthcare providers have shown certain resistance to intrauterine contraception due to the existence of misperceptions towards these methods. It is important to overcome these barriers, providing contrasted and truthful information about all existing methods, so that health professionals can provide complete contraceptive counselling for all women. This review approaches the clinically relevant aspects of the new LNG-IUS 19.5<!--> <!-->mg Kyleena<sup>®</sup> method and the benefits it can provide to women.</p></div>","PeriodicalId":100911,"journal":{"name":"Medicina Reproductiva y Embriología Clínica","volume":"5 2","pages":"Pages 61-70"},"PeriodicalIF":0.0000,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina Reproductiva y Embriología Clínica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2340932018300094","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The high rate of unwanted pregnancies results in a high social and economic impact worldwide. One of the most important strategies to reduce this problem is to increase the use of long-acting reversible contraceptive (LARC) methods, due to their efficacy, cost-effectiveness and the independence that these methods provide to their users. LARC methods have been shown to be safe for most women, regardless of age and parity. Kyleena® is the new LARC option. A new levonorgestrel intrauterine system (LNG-IUS) containing 19.5 mg of levonorgestrel and provides a high contraceptive efficacy over 5 years of use, with a cumulative 5-year Pearl Index of 0.29. Its small size allows a narrower insertion tube to be used and is more suitable for nulliparous women or those women with a narrower cervical canal. In addition to the contraceptive efficacy, Kyleena® may benefit users by providing a reduction in the duration and volume of menstrual bleeding. Many women and healthcare providers have shown certain resistance to intrauterine contraception due to the existence of misperceptions towards these methods. It is important to overcome these barriers, providing contrasted and truthful information about all existing methods, so that health professionals can provide complete contraceptive counselling for all women. This review approaches the clinically relevant aspects of the new LNG-IUS 19.5 mg Kyleena® method and the benefits it can provide to women.

新的slil - lng 19.5 mg及其在女性中的应用的证据和临床辩论
高意外怀孕率在世界范围内造成了严重的社会和经济影响。减少这一问题的最重要战略之一是增加使用长效可逆避孕方法,因为这些方法具有疗效、成本效益和独立性。LARC方法已被证明对大多数妇女是安全的,无论年龄和胎次。Kyleena®是新的LARC选项。一种新型左炔诺孕酮宫内系统(LNG-IUS),含19.5 mg左炔诺孕酮,使用5年避孕效果高,累计5年珍珠指数为0.29。它的小尺寸允许使用较窄的插入管,更适合无产妇女或宫颈管较窄的妇女。除了避孕功效外,Kyleena®还可以减少月经出血的持续时间和数量,从而使用户受益。由于对这些方法存在误解,许多妇女和保健提供者对宫内避孕表现出一定的抵制。必须克服这些障碍,提供有关所有现有方法的对比和真实信息,以便保健专业人员能够为所有妇女提供全面的避孕咨询。本文综述了新的LNG-IUS 19.5 mg Kyleena®方法的临床相关方面及其可为女性提供的益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信